Patient Characteristics, Response and Steroid Dose

Pt #GradeORKPS# of cycles of pembroMGMT StatusIDH Status1p/19qMLSteroids at initiationSteroid dose at initiation (in prednisone equivalence)# of cycles with steroidsConBevPrev Bev
0<20≥20
1IIIPR904unmethylatedWTN/A6NX2YY
2IVPR804unmethylatedN/AN/A6YX1YN
3IIISD9014methylatedWTintact6NX0NN
4IIISD7010unmethylatedMUTN/A3YX1YY
5IVSD9014unmethylatedWTN/A12NX5YY
6IVSD1004methylatedN/AN/A13NX0NY
7IVSD1001N/AWTN/AN/AYX1YY
8IIIPD906N/AMUTco-del5YX1NN
9IIIPD605N/AMUTco-del58YX0YY
10IIIPD603unmethylatedMUTN/A7NX2NN
11IIIPD703unmethylatedWTN/A5YX3YY
12IIIPD902unmethylatedWTintact15YX2YN
13IIIPD902unmethylatedMUTN/A7YX2YY
14IIIPDN/A1methylatedMUTN/A5NX0NY
15IVPD905methylatedMUTN/A11YX2NN
16IVPD605unmethylatedWTintact10YX2YY
17IVPD504N/AN/AN/AN/ANX0YY
18IVPD903N/AMUTN/A9YX3YY
19IVPD903unmethylatedN/AN/A4YX1YY
20IVPD903N/AN/AN/AN/ANX1YY
21IVPD702unmethylatedWTN/A13YX2YY
22IVPD802unmethylatedMUTN/A5NX0YY
23IVPD802N/AWTN/AN/ANX1YY
24N/APD702N/AN/AN/AN/ANX1YY
25IVN/A601N/AMUTintact19YX1YY

Abbreviations: Pt: Patient; OR: Objective response; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; KPS: Karnofsky performance score; Pembro: pembrolizumab; N/A: not applicable or unknown; MGMT methylated: methylated; MGMT unmethylated: unmethylated; IDH mutant: MUT; IDH wild type: WT; 1p19q intact: intact; 1p19q codeleted: Co-del; ML: mutational load by MSK impact; Y: yes; N: no; X: indicates steroid dose at initiation; Con Bev: Concomitant bevacizumab; Prev Bev: previously progressed on bevacizumab treatment